Eli Lilly Gains Ground on Novo Nordisk in GLP-1 Market with Oral Drug Progress
Novo Nordisk, the Danish pharmaceutical giant behind blockbuster drugs Ozempic and Wegovy, is seeing its dominance in the GLP-1 market challenged by longtime rival Eli Lilly. The U.S.-based firm has made significant clinical strides with its oral GLP-1 candidate orforglipron, positioning itself to potentially overtake Novo's lead in diabetes and weight management treatments.
Lilly's recent Achieve-2 trial results demonstrate orforglipron's superior A1C reduction capabilities compared to existing market leaders. This development comes as Novo Nordisk seeks FDA approval for an oral version of Wegovy, attempting to maintain its first-mover advantage in the weight management segment. The intensifying competition between these two healthcare titans mirrors their decades-long rivalry in diabetes medications.
